Trial NCT05124171; EudraCT 2021-004550-33
Publication Launay O, N Engl J Med, 2022
Primary outcome on the report: Percentage of participants who had an increase in the neutralizing-antibody titer by a factor of at least 10 between day 0 and day 15 after receipt of the booster as measured by microneutralization against the original D614 (wild-type) strain of SARS-CoV-2 or the B.1.351 (beta) variant.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.